INO
HealthcareInovio Pharmaceuticals, Inc.
$1.59
$-0.10 (-5.92%)
Jan 5, 2026
Price History (1Y)
Analysis
Inovio Pharmaceuticals, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $109.24M and 134 employees. The company's revenue for the trailing twelve months (TTM) was $182,337. The financial performance of Inovio Pharmaceuticals, Inc. indicates significant losses, with a net income of -$108,092,464 (TTM), an EBITDA of -$88,220,528, and free cash flow of -$798,461. The company's margins are also negative, including a gross margin of 0.0%, operating margin of -49,202.9%, and profit margin of 0.0%. In terms of returns, the company reported a return on equity (ROE) of -328.4% and return on assets (ROA) of -63.6%. The valuation context for Inovio Pharmaceuticals, Inc. is characterized by a forward P/E ratio of -1.06, price to sales ratio of 599.10, and an EV/EBITDA of -0.56. The company has $50.80M in cash and $10.02M in debt.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $109.24M
- P/E Ratio
- N/A
- 52-Week High
- $2.98
- 52-Week Low
- $1.30
- Avg Volume
- 1.42M
- Beta
- 1.63
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 134